This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
VISION Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Centers of Excellence
Urologic Oncology
Left Group
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Clinical Trials
From the Editor
Search Clinical Trials
Transformative Trials
DORA - PCCTC
IRONMAN - PCCTC
PROMISE - PCCTC
SPLASH Trial
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
RSNA 2022
SUO 2022
Urologists for Social Responsibility 2023
Upcoming
ASCO GU 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO 2021
ASCO 2021
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ASCO 2021 Bladder Cancer
Viewing 1-20 of 38 articles
ASCO 2021: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach – Urologic Oncologist Perspective
ASCO 2021: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach – Radiation Oncologist Perspective
ASCO 2021: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach – Medical Oncologist Perspective
ASCO 2021: Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy As Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial
ASCO 2021: Optimizing Urothelial Cancer Management from Organ-Confined to Metastatic Disease: A Multidisciplinary Approach
ASCO 2021: Phase 2 Trial of Gemcitabine, Cisplatin, plus Nivolumab with Selective Bladder Sparing in Patients with Muscle- Invasive Bladder Cancer (MIBC): HCRN GU 16-257
ASCO 2021: Conundrums in First-Line Urothelial Carcinoma: Are More Drugs Beyond Platinum Chemotherapy Always Better?
ASCO 2021: Inducible T-Cell Co-Stimulatory (ICOS) Receptor Agonist, Feladilimab (Fela), Alone and in Combination (Combo) with Pembrolizumab (P): Results from INDUCE-1 Urothelial Carcinoma (UC) Expansion Cohorts (ECs).
ASCO 2021: First-Line Pembrolizumab (Pembro) in Cisplatin-Ineligible Patients with Advanced Urothelial Cancer (UC): Response and Survival Results up to Five Years from the KEYNOTE-052 Phase 2 Study
ASCO 2021: Conundrums in First-Line Urothelial Carcinoma: Is More Always Better?
ASCO 2021: A Randomized Phase II Study Comparing Cisplatin and Gemcitabine with or Without Berzosertib in Patients with Advanced Urothelial Carcinoma
ASCO 2021: Inducible T-Cell Co-Stimulatory Receptor Agonist, Feladilimab, Alone and in Combination With Pembrolizumab: Results From INDUCE-1 Urothelial Carcinoma Expansion Cohorts
ASCO 2021: First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer: Response and Survival Results Up to Five Years From the KEYNOTE-052 Phase 2 Study
ASCO 2021: Steps Toward a Bladder-Intact Cure for Muscle-Invasive Bladder Cancer
ASCO 2021: Phase II Trial of Durvalumab Plus Tremelimumab With Concurrent Radiotherapy in Patients With Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach: IMMUNOPRESERVE-SOGUG Trial
ASCO 2021: Phase 2 Trial of Gemcitabine, Cisplatin, Plus Nivolumab With Selective Bladder Sparing in Patients With Muscle-Invasive Bladder Cancer: HCRN GU 16–257
ASCO 2021: Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy As Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer: A Multicenter Phase 2 Trial
ASCO 2021: Effect of BCG Exposure on Severity of COVID-19 Infection: A COVID-19 and Cancer Consortium (CCC19) Study
ASCO 2021: Barriers to Best Care: A Patient's Perspective
ASCO 2021: Immunotherapy as Curative Therapy in Advanced Kidney and Bladder Cancer: Fantasy or Reality?
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free